CIGAR BONE

Brand Owner Address Description
CIGARBONE HENK B.V. Gardermoenbaan 25 NL-3045 AX Rotterdam Netherlands CIGAR BONE;Advertising services; business management; business administration for others; providing office functions; retail and wholesale store services in relation to smokers' articles made of precious metal or coated therewith, namely, lighters, pots, cans and cases as well as other containers for cigarettes, cigars, smoking tobacco, chewing tobacco and matches, cigarette and cigar holders, cigar cutters, ashtrays, tobacco and tobacco products, in particular cigars, cigarillos, cigarettes, smoking tobacco, chewing tobacco, snuff, smokers' articles, cigarette cases, storage containers for cigars, also with humidor, ashtrays, not of precious metal, matches and boxes for matches, not of precious metal, lighters and boxes for lighters, not of precious metal;Tobacco and tobacco products, in particular cigars, cigarillos, cigarettes, smoking tobacco, chewing tobacco, snuff; smokers' articles, namely, cigar storage tubes, filter tubes, cigar glue, rehydration tubes, keystones for pipes; cigarette cases; storage containers for cigars in the nature of humidors; ashtrays, not of precious metal; matches and boxes for matches, not of precious metal; lighters for smokers and boxes for lighters for smokers, not of precious metal; smokers' articles made of precious metal or coated therewith, namely, lighters, pots, cans and cases for cigarettes, cigars, smoking tobacco, chewing tobacco and matches, cigarette and cigar holders, cigar cutters, and ashtrays;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. An agent for treatment of metabolic bone disease, which contains EPO as an active ingredient, or a method for treating a patient with metabolic bone disease, which comprises EPO, is provided. Pharmaceutical products containing EPO as the active ingredient are novel prophylactic and therapeutic agents which show an ameliorative action by healing bone and bone marrow lesions in bone disease, especially bone disease based on impaired bone metabolism, aside from the previously reported erythrocyte increasing action of EPO. Pathological states, targeted by these pharmaceutical products, are bone diseases showing metabolic bone disorders, including renal failure-associated osteodystrophy, marble bone disease, diabetic nephropathy, and osteoporosis.